New Report Projects Heart Failure Drug Sales to Reach $53B by 2032 Despite Barriers to Growth
-
Report provides insights into heart failure market across 7 major countries through 2032, with sales projected to reach $53B.
-
Growth driven by uptake of SGLT2 inhibitors and 3 first-in-class drugs entering market.
-
High costs of new therapies and physician reluctance pose challenges to growth.
-
Scope includes epidemiology, disease management, clinical trials, pipeline analysis, and market competition.
-
Profiles current and future players like Amgen, AstraZeneca, Novartis, and evaluates late-stage pipeline candidates.